CD34 and acute myeloid leukemia: One CD300f monoclonal antibody (mAb) that bound leukemic blasts but not CD34+ HSPCs in the majority of AMLs in a small cohort of human samples had some efficacy in a xenogeneic model of AML using the HL‐60 cell line (Korver et al., 2009).